Relationship of Insulin-Like Growth Factors System Gene Polymorphisms with the Susceptibility and Pathological Development of Hepatocellular Carcinoma

详细信息    查看全文

• 作者：Chia-Jui Weng PhD (1)
  Yi-Hsien Hsieh PhD (2)
  Chiung-Man Tsai MS (3)
  Yin-Hung Chu MS (4)
  Kwo-Chang Ueng PhD (4) (5)
  Yu-Fan Liu PhD (6)
  Yuan-Hung Yeh MD (4) (7)
  Shih-Chi Su MS (8)
  Yi-Chen Chen PhD (9)
  Mu-Kuan Chen MD ; PhD (10) (11) (4)
  Shun-Fa Yang PhD (12) (4)
  
• 刊名：Annals of Surgical Oncology
• 出版年：2010
• 出版时间：July 2010
• 年：2010
• 卷：17
• 期：7
• 页码：1808-1815
• 全文大小：248KB
• 参考文献：1. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. / Clin Liver Dis. 2005; 9:191-11. CrossRef
  2. Department of Health, Republic of China. Health statistics: II. Vital statistics. Taipei: Department of Health, 2007.
  3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. / Nat Rev Cancer. 2006;6:674-7. CrossRef
  4. Firpi RJ, Nelson DR. Viral hepatitis: manifestations and management strategy. / Hematology Am Soc Hematol Educ Program. 2006;375-0.
  5. Yano Y, Yamashita F, Kuwaki K, et al. Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II. / Liver Int. 2006;26:789-95. CrossRef
  6. Akk?z H, Bayram S, Bekar A, et al. G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: Case-control study. / Cancer Epidemiol. 2009 (in press).
  7. Chang CC, Chen SC, Hsieh YH, et al. Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma. / Clin Chem Lab Med. 2009;47:412-8. CrossRef
  8. Liu JP, Baker J, Perkins AS, et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGFI) and type I IGF receptor (IGFIr) / . Cell 1993;75:59-2.
  9. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. / Nat Rev Cancer. 2004;4:505-8. CrossRef
  10. Gomes MV, Soares MR, Pasqualim-Neto A, Marcondes CR, L?bo RB, Ramos ES. Association between birth weight, body mass index and IGF2/ApaI polymorphism. / Growth Horm IGF Res. 2005;15:360-2. CrossRef
  11. LeRoith D, Roberts Jr. CT. The insulin-like growth factor system and cancer. / Cancer Lett. 2003;195:127-7.
  12. LeRoith D, Werner H, Beitner-Johnson D, et al. Molecular and cellular aspects of the insulin-like growth factor I receptor. / Endocr Rev. 1995;16:143-3.
  13. Chao W, D’Amore PA. IGF2: Epigenetic regulation and role in development and disease. / Cytokine Growth Factor Rev. 2008;19:111-0. CrossRef
  14. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. / Nat Rev Drug Discov. 2008;6:821-3. CrossRef
  15. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer. / Nat Clin Pract Oncol. 2008;4:591-02. CrossRef
  16. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. / Arterioscler Thromb Vasc Biol. 2004;24:435-4. CrossRef
  17. Cheng I, Stram DO, Penney KL et al. Common genetic variation in IGF1 and prostate cancer risk in the multiethnic cohort. / J Natl Cancer Inst. 2006;98:123-4. CrossRef
  18. Deming SL, Ren Z, Wen W, Shu XO, Cai Q, Gao YT, et al. Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study. / Breast Cancer Res Treat. 2007;104:309-9. CrossRef
  19. Kaku K, OsadH a, Seki K, Sekiya S. Insulin-like growth factor 2 (IGF2) and IGF2 receptor gene variants are associated with fetal growth. / Acta / Paediatrica. 2007;96:363-. CrossRef
  20. Ho GY, Melman A, Liu SM, et al. Polymorphism of the insulin gene is associated with increased prostate cancer risk. / Br J Cancer. 2003;88:263-. CrossRef
  21. Rezgui D, Williams C, Savage SA, et al. Structure and function of the human Gly1619Arg polymorphism of M6P/IGF2R domain 11 implicated in IGF2 dependent growth. / J Mol Endocrinol. 2009;42:341-6. CrossRef
  22. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. Molecular interactions of the IGF system. / Cytokine Growth Factor Rev. 2005;16:421-9. CrossRef
  23. DaCosta SA, Schumaker LM, Ellis MJ. Mannose 6-phosphate/insulin-like growth factor 2 receptor, a bona fide tumor suppressor gene or just a promising candidate? / J Mammary Gland Biol Neoplasia. 2000;5:85-4. CrossRef
  24. Oates AJ, Schumaker LM, Jenkins SB, et al. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. / Breast Cancer Res Treat 1998;47:269-1. CrossRef
  25. Cohen P. Insulin-like growth factor binding protein-3: insulin-like growth factor independence comes of age. / Endocrinology. 2006;147:2109-1. CrossRef
  26. Hoyo C, Grubber J, Demark-Wahnefried W, et al. Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites. / J Natl Med Assoc. 2007;99:718-2.
  27. Claeys GB, Sarma AV, Dunn RL, et al. INSPstI polymorphism and prostate cancer in African-American men. / Prostate. 2005;65:83-. CrossRef
  28. Centers for Disease Control, Taiwan, 2007. http://www.cdc.gov.tw.
  29. Wu X, Yu H, Amos CI, Hong WK, Spitz MR. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. / J Natl Cancer Inst. 2000;92:737-3. CrossRef
  30. Hankinson L, Strohm O, Osterziel K, et al. Insulin-like growth factor-I and risk of breast cancer. / Lancet. 1998;352:489-9. CrossRef
  31. Stattin P, Rinaldi S, Biessy C, et al. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based non-screened cohort. / J Clin Oncol. 2004;22:3104-2. CrossRef
  32. El Atiq F, Garrouste F, Remacle-Bonnet M, et al. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. / Int J Cancer. 1994;57:491-7. CrossRef
  33. Ma J, Pollak M, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. / J Natl Cancer Inst. 1999;91:628-.
  34. Palmqvist R, Hallmans G, Rinaldi S, et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. / Gut. 2002;50:642-. CrossRef
  35. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. / J Cell Physiol. 2000;183:1-. CrossRef
  36. Jacobs CI. A review of the role of insulin-like growth factor 2 in malignancy and its potential as a modifier of radiation sensitivity. / Clin Oncol ( / R Coll Radiol). 2008; 20:345-2.
  37. Hahn H, Wojnowski L, Specht K, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. / J Biol Chem. 2000;275:28341-4. CrossRef
  38. Kotsinas A, Evangelou K, Sideridou M, et al. The 3-UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer. / Cancer Lett. 2008;259:177-5. CrossRef
  39. Jang HS, Kang KM, Choi BO, Chai GY, Hong SC, Ha WS, et al. Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma. / World J Gastroenterol. 2008;14:1394-. CrossRef
  40. Ren Z, Cai Q, Shu XO, et al. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. / Cancer Epidemiol Biomarkers Prev. 2004;13:1290-.
  41. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. / J Clin Endocrinol Metab. 2001;86:1274-0. CrossRef
  42. Tsai MC, Kee KM, Chen YD, et al. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. / J Gastroenterol Hepatol. 2007;22:92-. CrossRef
  43. Kumar M, Kumar R, Hissar SS, et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India. / J Gastroenterol Hepatol. 2007;22:1104-1. CrossRef
  44. Fuke H, Sugimoto K, Shiraki K, et al. Predictive factors for distant recurrence of HCV-related hepatocellular carcinoma after radiofrequency ablation combined with chemoembolization. / Aliment Pharmacol Ther. 2008;27:1253-0. CrossRef
  45. Changchien CS, Chen CL, Yen YH, et al. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. / J Gastroenterol. 2008;43:159-0. CrossRef
  
• 作者单位：Chia-Jui Weng PhD (1)
  Yi-Hsien Hsieh PhD (2)
  Chiung-Man Tsai MS (3)
  Yin-Hung Chu MS (4)
  Kwo-Chang Ueng PhD (4) (5)
  Yu-Fan Liu PhD (6)
  Yuan-Hung Yeh MD (4) (7)
  Shih-Chi Su MS (8)
  Yi-Chen Chen PhD (9)
  Mu-Kuan Chen MD, PhD (10) (11) (4)
  Shun-Fa Yang PhD (12) (4)
  
  1. Graduate Institute of Applied Science of Living, Tainan University of Technology, Tainan, Taiwan
  2. Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan
  3. Chest Hospital, Department of Health, Executive Yuan, Tainan, Taiwan
  4. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
  5. Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan
  6. Department of Biomedical Sciences, Chung Shan Medical University, Taichung, Taiwan
  7. Yang-Ming Rehabilitation Clinic, Taichung, Taiwan
  8. Department of Molecular and Cellular Medicine, Texas A&M University System Health Science Center, College Station, TX, USA
  9. School of Nutrition, Chung Shan Medical University, Taichung, Taiwan
  10. Department of Otorhinolaryngology-Head and Neck Surgery, Changhua Christian Hospital, Changhua, Taiwan
  11. Mingdao University, Changhua, Taiwan
  12. Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan
  

文摘

Background Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related death worldwide. The insulin-like growth factors (IGFs) system consists of a group of proteins which may induce cell proliferation and inhibit cell apoptosis through several signal pathways, leading to transformation of normal cells into cancer cells. However, the impact of genetic polymorphisms of the IGFs system on HCC has not been clarified. Methods In this case–control study, a total of 102 HCC patients and 306 age- and gender-matched controls were recruited. The genetic polymorphisms of the IGFs system genes, including IGF-1, IGF-2, IGF-1receptor (IGF-1R), IGF-2R, IGF binding protein (IGFBP-3), and insulin (INS) genes, were analyzed by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) and real-time PCR genotyping analysis. Results A significant difference (p?=?0.02) between case and control group in the distribution frequency of IGF-2 +3580 polymorphism was observed. Multiple regression model analysis showed that the presence of AA or AG at IGF-2R may exhibit a potential protective effect against hepatitis C [odds ratio (OR)?=?0.35, 95% confidence interval (CI)?=?0.15-.82]. The combination of IGF-2 +3580 AA genotype and IGF-2R GG genotype may present a significantly lower risk of HCC (OR?=?0.20, 95% CI?=?0.05-.87). Additionally, no polymorphisms of any IGFs system genes were associated with liver-related clinicopathological markers in serum. Conclusions Among IGFs system genes, IGF-2 and IGF-2R gene polymorphisms and combination could be considered as the most important factors contributing to increased susceptibility and pathological development of HCC.